Author: admin

  • Andrew Percy – 2016 Parliamentary Question to the Department of Health

    Andrew Percy – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

    To ask the Secretary of State for Health, what steps his Department has taken to encourage the use of faecal calprotectin in primary care to facilitate prompt and appropriate referral of people with suspected inflammation of the bowel.

    Jane Ellison

    The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.

    The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.

    No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.

    Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.

    The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

    The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.

  • Derek Thomas – 2016 Parliamentary Question to the Department of Health

    Derek Thomas – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Derek Thomas on 2016-03-24.

    To ask the Secretary of State for Health, if he will issue guidance to NHS trusts on ensuring future reductions in frontline staff numbers are not made for the purpose of reducing trusts’ deficits.

    Ben Gummer

    The National Health Service has taken a number of steps to reduce trusts’ deficits. We have introduced tough new financial controls to cut down on waste in the NHS – including clamping down on rip-off staffing agencies and expensive management consultants, and introducing central procurement rules.

    We are also introducing a £2.1 billion Sustainability and Transformation Fund in 2016/17 to support providers to move to a financially sustainable footing. This will give the NHS the space to transform services so they are world class for decades to come.

    The purpose of these actions is to put NHS finances on a sustainable footing to ensure high quality care, now and in the future.

    Trusts should focus on the numbers and skillmix needed to deliver quality care, patient safety and efficiency, taking into account local factors such as acuity and casemix.

    Two communications to NHS trusts (a letter on safe staffing and efficiency dated 13 October 2015 from NHS Improvement, the Care Quality Commission (CQC), NHS England, Jane Cummings, Chief Nursing Officer and the National Institute for Health and Care Excellence; and a letter dated 15 January 2016 from Chief Executive-designate of NHS Improvement, Jim Mackey, and the CQC’s Chief Inspector of Hospitals, Professor Sir Mike Richards) asked trusts to consider quality and finances on an equal footing in their planning decisions; stated that it is not the case that NHS trusts could only achieve their financial targets at the expense of quality, or that improving quality is more important than staying in financial surplus; and emphasised that responsibility for staffing rests (as it has always done) with trust boards.

  • Luciana Berger – 2016 Parliamentary Question to the Department of Health

    Luciana Berger – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2016-03-24.

    To ask the Secretary of State for Health, pursuant to the Answer of 18 January 2016 to Question 22159, on mental illness and A&E departments, if he will publish that data for each month of 2015 and 2016.

    Alistair Burt

    There are no plans to routinely publish the number of accident and emergency attendances with a duration to departure of more than four hours, for patients with a primary diagnosis of psychosis, by age group.

  • Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2016-03-24.

    To ask the Secretary of State for Health, if his Department will meet with NICE, NHS England and Vertex to discuss the provision on the NHS of the drug Orkambi to treat cystic fibrosis.

    George Freeman

    The National Institute for Health and Care Excellence (NICE) is currently consulting on its draft technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. Stakeholders, including the Department, NHS England and the manufacturer, Vertex Pharmaceuticals, now have an opportunity to comment on this draft guidance.

    Departmental officials remain ready to discuss any proposals from the company that could enable National Health Service patients to access the drug at a cost-effective price.

    NICE expects to publish its final guidance in July 2016.

  • Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2016-03-24.

    To ask the Secretary of State for Health, for what reason NHS England decided not to proceed with the Truvada commissioning process; and what plans the Government has to make that drug available on the NHS.

    Jane Ellison

    NHS England does not now consider pre-exposure prophylaxis (PrEP) for HIV is suitable for prioritisation of specialised commissioning spend as it is a preventative measure. However given the potential benefits in this area, NHS England is keen to build on the work to date and will be making available up to £2 million over the next two years to run a number of early implementer test sites. These will be undertaken in conjunction with Public Health England and will seek to answer the remaining questions around how PrEP could be commissioned in the most cost effective and integrated way to reduce HIV and sexually transmitted infections in those at highest risk.

  • Luciana Berger – 2016 Parliamentary Question to the Department of Health

    Luciana Berger – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2016-03-24.

    To ask the Secretary of State for Health, what progress he has made on implementing recommendation 10 in the executive summary of Public Health England’s March 2015 report entitled, Public mental health leadership and workforce development framework, on building the capacity of the National Mental Health Intelligence Network.

    Jane Ellison

    Progress on implementing recommendation 10, which is to build the mental health intelligence capability through the National Mental Health Intelligence Network (NMHIN) can be categorised into three sections and is as follows:

    1) Capacity – NMHIN increased capacity in 2015/16 through NHS England investment. This enabled recruitment to work on additional/enhanced programmes on Crisis Care and Perinatal Mental Health and the first stage of a mental health Joint Strategic Needs Assessment toolkit. NHS England have committed to continue investment in 2016/17.

    2) Products – the NMHIN has enhanced mental health intelligence capability through the development of;

    a) Profiling tools (i.e. new tool on Suicide Prevention; expanded tool on Severe Mental Illness and Common Mental Health Disorders; updated tools which include; Children and Young People’s Mental Health and Wellbeing) and,

    b) ntelligence products (i.e. Measuring Mental Wellbeing in Children and Young People).

    3) Dissemination – the NMHIN has enabled more people to use mental health intelligence through a communication and training programme that provides: routine updates on products and work programmes, training sessions on using products, online access to video and document guides, and a programme of presentations that promote products and encourages use. The Public Health England Local Intelligence Service support this programme and increasingly a range of partners request sessions.

  • Royston Smith – 2016 Parliamentary Question to the Department of Health

    Royston Smith – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Royston Smith on 2016-03-24.

    To ask the Secretary of State for Health, what proportion of NHS funding was provided to GP surgeries in each of the last five years

    Alistair Burt

    NHS England has confirmed that the funding it invests in general practice will increase by an average of 4.5% each year from 2016/17 to 2020/21.

    The below table shows the proportion of spend on general practice for each of the last five years for which data is available. The figures for spend on general practice are taken from the Health and Social Care Information Centre’s Investment in General Practice 2011-2015 report, which is the most comprehensive source of data on investment in general practice. The NHS Revenue Expenditure data is taken from the Department’s accounts.

    2010/11

    2011/12

    2012/13

    2013/14

    2014/15

    NHS Revenue Expenditure under Clear Line of Sight Rules (£ billion)

    97.47

    100.27

    102.57

    106.5

    110.56

    Spend on general practice (£ billion)

    8.350

    8.397

    8.459

    8.766

    9.001

    Spend on General Practice as a proportion of total

    8.6%

    8.4%

    8.2%

    8.2%

    8.1%
  • Stuart Blair Donaldson – 2016 Parliamentary Question to the Home Office

    Stuart Blair Donaldson – 2016 Parliamentary Question to the Home Office

    The below Parliamentary question was asked by Stuart Blair Donaldson on 2016-03-24.

    To ask the Secretary of State for the Home Department, how many colleges and universities have had (a) sponsorship licences revoked and (b) faced other restrictions related to allegations of English Language Test fraud; and what steps she plans to take to reconsider those revocations and restrictions.

    Mike Penning

    This data is published on the following website:

    https://www.gov.uk/government/publications/temporary-and-permanent-migration-data-february-2016

    As this is linked to ongoing litigation, it would be inappropriate to comment further at this time.

  • Stuart C. McDonald – 2016 Parliamentary Question to the Home Office

    Stuart C. McDonald – 2016 Parliamentary Question to the Home Office

    The below Parliamentary question was asked by Stuart C. McDonald on 2016-03-24.

    To ask the Secretary of State for the Home Department, if she will estimate the number of people affected by the decision of 23 March 2016 of the Upper Tribunal (Immigration and Asylum Chamber) in the case Qadir v Secretary of State; and what steps she plans to take to (a) notify those people affected and (b) support appeals of previous immigration decisions by those people affected.

    Mike Penning

    We are disappointed by the decision in Qadir and SM and, once we have the full determination, we will consider challenging it. Until we have the full determination, we cannot make an assessment of the number of persons affected.

  • Richard Burgon – 2016 Parliamentary Question to the Home Office

    Richard Burgon – 2016 Parliamentary Question to the Home Office

    The below Parliamentary question was asked by Richard Burgon on 2016-03-24.

    To ask the Secretary of State for the Home Department, what process Tier 2 intra-company transfer visas for IT undergo when they reach her Department.

    Mike Penning

    The process for handling Tier 2 intra company transfer (ICT) visas for IT is the same as that for any other application under the Tier 2 intra company transfer arrangements. All applications are validated to ensure the correct fees have been paid, all mandatory questions have been answered on the forms, and applicants have submitted their biometric information. Checks are also undertaken on every application to assess any adverse immigration or security issues.